Brian Douglass compensation by year
REPLIGEN Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $417,150 |
| Bonus | $0 |
| Stock awards | $912,284 |
| Option awards | $184,404 |
| Non-equity incentive | $212,747 |
| Pension and deferred compensation | $0 |
| All other | $8,209 |
| Total | $1,734,794 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: REPLIGEN CORP DEF 14A filed April 2, 2026, accession 0001193125-26-140115, and prior-year filings.
How this page was built: the REPLIGEN CORP filed document, accession 0001193125-26-140115. Every figure is read from that document and cited to the page and table it appears in. Filed April 2, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 4,000 | $655,440 | — |
| RSU | 2,288 | $374,912 | — |
| RSU | 2,252 | $369,013 | — |
| PSU | 1,144 | $187,456 | — |
| Option | 8,000 | — | $167.72 |
| Option | 2,143 | — | $163.86 |
Per the Outstanding Equity Awards at Fiscal Year-End table in REPLIGEN CORP's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments REPLIGEN discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $450,000 | $218,425 | — | $668,425 |
| Change in control and involuntary termination | $1,181,250 | $842,896 | — | $2,361,646 |
Per the Potential Payments Upon Termination or Change in Control table in REPLIGEN CORP's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
REPLIGEN’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Olivier Loeillot | President and Chief Executive Officer | $6,114,771 |
| Jason Garland | Chief Financial Officer | $2,988,322 |
| James Bylund | Chief Operating Officer | $2,932,519 |
| Ralf Kuriyel | Senior Vice President, Research and Development | $2,328,921 |
| Brian Douglass · this page | Senior Vice President, Chief Product Officer | $1,734,794 |
Brian Douglass's compensation dossier, REPLIGEN
You have read Brian Douglass's totals and holdings. The dossier adds each equity grant REPLIGEN disclosed for Brian Douglass and REPLIGEN's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full REPLIGEN compensation record
free company briefThis page is one person within REPLIGEN's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the REPLIGEN proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order REPLIGEN's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are REPLIGEN's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.